Xeris Pharmaceuticals, Inc. (XERS) 


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Xeris Pharmaceuticals, Inc. ("Xeris" or "the Company") (NASDAQ: XERS). The investigation concerns whether Xeris and certain of its officers and/or directors have violated federal securities laws.


On or around June 20, 2018, Xeris conducted its initial public offering (“IPO”), selling 5,700,000 shares of common stock priced at $15.00 per share.  On March 9, 2021, Xeris issued a press release announcing its fourth quarter and full year 2020 results.  Among other results, Xeris reported fourth quarter GAAP earnings per share of $0.41, missing consensus estimates by $0.01, and revenue of $7.09 million, missing consensus estimates by $1.82 million.  On this news, Xeris’s stock price fell $0.11 per share, or 2.33%, to close at $4.61 per share on March 9, 2021.  Since the IPO, Xeris’s stock price has closed as low as $1.49 per share, representing a decline of more than 90% from the offering price.


If you are aware of any facts relating to this investigation, or purchased Xeris shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.